Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PTX
- CUSIP: 71426V10
- Web: www.pernixtx.com
Capitalization:- Market Cap: $45.77 million
- Outstanding Shares: 10,015,000
Average Prices:- 50 Day Moving Avg: $4.28
- 200 Day Moving Avg: $3.80
- 52 Week Range: $1.83 - $10.40
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $138.13 million
- Price / Sales: 0.33
- Book Value: ($14.26) per share
- Price / Book: -0.31
Profitability:- EBIDTA: $1.79 million
- Net Margins: -125.33%
- Return on Assets: -36.64%
Debt:- Debt-to-Equity Ratio: -0.83%
- Current Ratio: 0.88%
- Quick Ratio: 0.79%
Misc:- Average Volume: 418,002 shs.
- Beta: 1.69
- Short Ratio: 12.27
Frequently Asked Questions for Pernix Therapeutics Holdings (NASDAQ:PTX)
What is Pernix Therapeutics Holdings' stock symbol?
Pernix Therapeutics Holdings trades on the NASDAQ under the ticker symbol "PTX."
How were Pernix Therapeutics Holdings' earnings last quarter?
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($2.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.80) by $1.86. The business had revenue of $29.74 million for the quarter. View Pernix Therapeutics Holdings' Earnings History.
Who are some of Pernix Therapeutics Holdings' key competitors?
Some companies that are related to Pernix Therapeutics Holdings include Intellipharmaceutics International (IPCI), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL), Innocoll Holdings (INNL), Neuralstem (CUR), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Amryt Pharma PLC (AMYT), BioLife Solutions (BLFS), Histogenics Corporation (HSGX), Evoke Pharma (EVOK), Marinus Pharmaceuticals (MRNS), Immune Pharmaceuticals (IMNP), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Galena Biopharma (GALE), Apricus Biosciences (APRI) and Aegerion Pharmaceuticals (AEGR).
Who are Pernix Therapeutics Holdings' key executives?
Pernix Therapeutics Holdings' management team includes the folowing people:
- John A. Sedor, Chairman of the Board, Chief Executive Officer
- Graham G. Miao Ph.D., President, Chief Financial Officer, Director
- Kenneth Robert Pina, Senior Vice President, Chief Compliance Officer, General Counsel
- Michael Joseph Golembiewski, Vice President, Corporate Controller, Principal Accounting Officer
- Dennis H. Langer M.D., J.D., Independent Director
- Gabriel S. Leung, Independent Director
- Tasos G Konidaris, Non-Executive Independent Director
How do I buy Pernix Therapeutics Holdings stock?
Shares of Pernix Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pernix Therapeutics Holdings' stock price today?
One share of Pernix Therapeutics Holdings stock can currently be purchased for approximately $4.49.
MarketBeat Community Rating for Pernix Therapeutics Holdings (NASDAQ PTX)MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pernix Therapeutics Holdings (NASDAQ:PTX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/12/2016 | Brean Capital | Downgrade | Buy -> Hold | | N/A |  |
| 3/23/2016 | S&P Equity Research | Lower Price Target | | $1.37 -> $1.12 | N/A | |
| 3/16/2016 | Oppenheimer Holdings, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 3/10/2016 | Needham & Company LLC | Downgrade | Buy -> Hold | | N/A | |
| 3/2/2016 | JMP Securities | Lower Price Target | Market Outperform | $8.00 -> $6.00 | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Pernix Therapeutics Holdings (NASDAQ:PTX)Earnings History by Quarter for Pernix Therapeutics Holdings (NASDAQ PTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/15/2017 | Q1 2017 | ($4.80) | ($2.94) | | $29.74 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.60) | ($2.99) | $48.60 million | $41.50 million | View | N/A | |
| 8/11/2016 | Q2 | ($0.08) | ($0.47) | $46.98 million | $36.75 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.06) | ($0.42) | $44.55 million | $32.50 million | View | N/A | |
| 3/10/2016 | Q4 | $0.01 | ($0.59) | $47.95 million | $46.37 million | View | Listen | |
| 11/5/2015 | Q315 | $0.01 | $0.08 | $46.83 million | $48.60 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.01) | ($0.10) | $50.70 million | $47.00 million | View | N/A | |
| 5/1/2015 | Q115 | $0.04 | ($0.11) | $34.55 million | $33.90 million | View | N/A | |
| 2/25/2015 | Q414 | $0.18 | $0.25 | $52.70 million | $53.00 million | View | N/A | |
| 11/10/2014 | Q314 | | ($0.02) | $28.10 million | $31.50 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.05) | ($0.16) | $26.20 million | $17.40 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.26) | $23.65 million | $19.10 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.10) | ($0.15) | $23.82 million | $23.90 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.13) | ($0.16) | $23.06 million | $18.30 million | View | Listen | |
| 8/9/2013 | Q2 2013 | ($0.13) | ($0.16) | $20.82 million | $20.60 million | View | N/A | |
| 5/10/2013 | Q1 2013 | $0.02 | ($0.05) | | | View | N/A | |
| 11/14/2012 | Q312 | $0.03 | ($0.01) | $15.04 million | $18.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pernix Therapeutics Holdings (NASDAQ:PTX)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Pernix Therapeutics Holdings (NASDAQ:PTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pernix Therapeutics Holdings (NASDAQ:PTX)Insider Ownership Percentage: 5.62%
Institutional Ownership Percentage: 17.34%
Insider Trades by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/19/2015 | Sanjay S Patel | CFO | Buy | 5,000 | $4.60 | $23,000.00 | |
| 8/18/2015 | Douglas Drysdale | CEO | Buy | 8,500 | $4.69 | $39,865.00 | |
| 5/6/2015 | Douglas Drysdale | CEO | Buy | 16,000 | $6.40 | $102,400.00 | |
| 5/6/2015 | Sanjay S Patel | CFO | Buy | 2,000 | $6.42 | $12,840.00 | |
| 11/3/2014 | Tracy Simmons Clifford | Insider | Sell | 2,246 | $10.00 | $22,460.00 | |
| 10/28/2014 | Tracy Simmons Clifford | Insider | Sell | 12,754 | $10.00 | $127,540.00 | |
| 5/21/2014 | James Edward Jr. Smith | major shareholder | Sell | 194,600 | $6.13 | $1,192,898.00 | |
| 5/16/2014 | James Edward Jr. Smith | major shareholder | Sell | 310,200 | $6.12 | $1,898,424.00 | |
| 5/14/2014 | James Edward Jr. Smith | major shareholder | Sell | 289,400 | $5.47 | $1,583,018.00 | |
| 5/9/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.37 | $196,650.00 | |
| 5/6/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.44 | $199,800.00 | |
| 5/1/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.68 | $140,400.00 | |
| 4/29/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.88 | $146,400.00 | |
| 4/25/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $5.20 | $156,000.00 | |
| 4/24/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.94 | $148,200.00 | |
| 4/17/2014 | James Edward Jr. Smith | major shareholder | Sell | 20,000 | $4.35 | $87,000.00 | |
| 4/15/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.63 | $208,350.00 | |
| 4/10/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.03 | $226,350.00 | |
| 4/7/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.90 | $220,500.00 | |
| 4/2/2014 | Cooper Collins | Insider | Sell | 90,000 | $5.26 | $473,400.00 | |
| 4/2/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.26 | $236,700.00 | |
| 3/28/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.47 | $246,150.00 | |
| 3/25/2014 | James Edward Jr. Smith | major shareholder | Sell | 255,000 | $4.21 | $1,073,550.00 | |
| 3/4/2014 | Cooper Collins | Insider | Sell | 3,590,000 | $3.40 | $12,206,000.00 | |
| 2/5/2014 | Cooper Collins | major shareholder | Sell | 90,000 | $2.22 | $199,800.00 | |
| 1/7/2014 | Cooper Collins | major shareholder | Sell | 27,962 | $2.20 | $61,516.40 | |
| 1/6/2014 | Cooper Collins | major shareholder | Sell | 62,038 | $2.35 | $145,789.30 | |
| 12/6/2013 | Cooper Collins | major shareholder | Sell | 37,452 | $2.31 | $86,514.12 | |
| 12/4/2013 | Cooper Collins | major shareholder | Sell | 52,548 | $2.44 | $128,217.12 | |
| 11/5/2013 | Cooper C Collins | Major Shareholder | Sell | 90,000 | $2.01 | $180,900.00 | |
| 10/8/2013 | Cooper Collins | major shareholder | Sell | 23,364 | $2.47 | $57,709.08 | |
| 10/9/2012 | Michael Cooper Pearce | Director | Sell | 1,288 | $8.00 | $10,304.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pernix Therapeutics Holdings (NASDAQ:PTX)
Latest Headlines for Pernix Therapeutics Holdings (NASDAQ:PTX)
| Source: |
|
| Date | Headline |
|---|
 | Pernix Therapeutics (PTX) Reports Prelim. Q2 Revenue of $33M-$35M
www.streetinsider.com - July 21 at 6:27 AM |
 | Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
finance.yahoo.com - July 21 at 6:27 AM |
| Pernix Commences Refinancing Transactions to Fortify Balance Sheet
finance.yahoo.com - July 21 at 6:27 AM |
 | Gainers & Losers Of July 13: PTX, ALDR, MNKD, TSRO, TOCA...
www.finanznachrichten.de - July 14 at 7:42 AM |
 | Breakfast Technical Briefing on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Pernix Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:52 AM |
 | Pernix Therapeutics Holdings, Inc. (PTX) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - July 8 at 10:10 PM |
| Pernix Therapeutics Added to Russell Microcap® Index
finance.yahoo.com - June 29 at 6:20 AM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : June 13, 2017
finance.yahoo.com - June 13 at 7:29 PM |
| Pernix Therapeutics Holdings, Inc. (PTX) Short Interest Update
www.americanbankingnews.com - June 11 at 10:52 PM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 31, 2017
finance.yahoo.com - May 31 at 12:58 PM |
| Edited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 21 at 6:25 PM |
| Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 12:12 PM |
 | Earnings Reaction History: Pernix Therapeutics Holdings, Inc., 44.4% Follow-Through Indicator, 11.8% Sensitive - Nasdaq
www.nasdaq.com - May 17 at 8:22 AM |
| Pre-Open Movers 05/16: (AKBA) (ETSY) (SINA) Higher; (PTX) (DKS) (SSYS) Lower (more...)
www.streetinsider.com - May 16 at 7:03 PM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 7:03 PM |
| Pernix Therapeutics Holdings Inc (PTX) Announces Quarterly Earnings Results, Beats Estimates By $1.86 EPS
www.americanbankingnews.com - May 16 at 1:34 PM |
 | BRIEF-Pernix Therapeutics qtrly loss per share $2.94
www.reuters.com - May 16 at 9:41 AM |
| Investor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 6:38 PM |
| Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 6:38 PM |
| Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
finance.yahoo.com - May 8 at 6:45 PM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 7:36 PM |
| Pernix Therapeutics Holdings (PTX) Given Daily News Impact Score of 0.56
www.americanbankingnews.com - May 2 at 4:20 PM |
| Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
finance.yahoo.com - May 1 at 11:05 AM |
| Somewhat Negative Media Coverage Very Likely to Affect Pernix Therapeutics Holdings (PTX) Stock Price
www.americanbankingnews.com - April 26 at 1:46 PM |
| Rennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps - Yahoo Finance
finance.yahoo.com - April 24 at 2:32 PM |
| Pernix Therapeutics Holdings (PTX) Receiving Critical News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 9:05 AM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 7:21 PM |
| Platinex Inc.-Proposed Private Placement
finance.yahoo.com - April 18 at 6:40 PM |
| Critical Media Coverage Very Likely to Effect Pernix Therapeutics Holdings (PTX) Share Price
www.americanbankingnews.com - April 15 at 12:09 PM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:43 PM |
| Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 12:05 PM |
| Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT
finance.yahoo.com - March 29 at 8:55 AM |
| Pernix Therapeutics Holdings Inc (PTX) Short Interest Down 22.7% in March
www.americanbankingnews.com - March 29 at 8:11 AM |
 | Pernix Therapeutics Holdings (PTX) Jumps with Q4 Earnings on Way
www.baystreet.ca - March 28 at 7:12 PM |
| Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 28 at 7:12 PM |
| PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 28 at 7:12 PM |
 | Earnings Scheduled For March 28, 2017 - Benzinga
www.benzinga.com - March 28 at 9:37 AM |
| 25 Stocks Moving In Tuesday's Pre-Market Session - Benzinga
www.benzinga.com - March 28 at 9:37 AM |
| Q4 2016 Pernix Therapeutics Holdings Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 9:37 AM |
| Pernix Therapeutics Holdings Inc (PTX) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - March 27 at 7:23 AM |
 | An Investor's Rationale To Staying Long Pernix Therapeutics
seekingalpha.com - March 24 at 7:14 PM |
| Pernix: An Investor's Rationale to Staying Long
finance.yahoo.com - March 23 at 7:50 PM |
| Pernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend ... - StreetInsider.com
www.streetinsider.com - March 23 at 12:19 AM |
| Pernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend Interim Settlement Agreement
www.streetinsider.com - March 21 at 7:08 PM |
 | Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28 - GlobeNewswire (press release)
globenewswire.com - March 16 at 12:34 AM |
| 20 Stocks Moving In Monday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - March 6 at 6:45 PM |
| Pre-Market Most Active for Feb 23, 2017 : CNHI, CLD, CHK, BAC, TSLA, BSX, LB, PTX, CTRP, NVDA, ERIC, TVIX - Nasdaq
www.nasdaq.com - February 24 at 8:17 AM |
| Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation - GlobeNewswire (press release)
globenewswire.com - February 24 at 8:17 AM |
 | 8:02 am Pernix Therapeutics confirmed received favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER
us.rd.yahoo.com - February 24 at 12:31 AM |
| Pernix Therapeutics (PTX) Wins Zohydro ER ANDA Litigation
www.streetinsider.com - February 23 at 7:29 PM |
Pernix Therapeutics Holdings (PTX) Chart for Friday, July, 21, 2017
